Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues to Demonstrate Positive Trends in the Week 48 Analysis
December 06, 2016 16:05 ET
|
Anthera Pharmaceuticals, Inc.
Lower proteinuria in blisibimod versus placebo treated patientsChanges in circulating B-cells and serum immunoglobulins consistent with BAFF inhibition HAYWARD, Calif., Dec. 06, 2016 (GLOBE...
Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients with Active Systemic Lupus Erythematosus
November 10, 2016 07:00 ET
|
Anthera Pharmaceuticals, Inc.
Assessing next steps for blisibimod for the treatment of Systemic Lupus ErythematosusContinuing to explore blisibimod as treatment for IgA nephropathy – Phase 2 data in...
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results
November 04, 2016 08:30 ET
|
Anthera Pharmaceuticals, Inc.
Blisibimod topline data from the Phase 3 CHABLIS-SC1 Study in severe lupus patients is imminentData and Safety Monitoring Board recommendation to continue SOLUTION study with Sollpura™FDA Type C...
Anthera Announces That Data From the Phase 2 BRIGHT-SC Study Has Been Accepted as a Late Breaking Abstract at the ASN Kidney Week 2016 Annual Meeting
November 02, 2016 12:58 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that an abstract of the interim data from the Phase 2 BRIGHT-SC clinical study...
Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct Offering to Biotechnology Value Fund and Rock Springs Capital
September 08, 2016 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has agreed to sell preferred convertible stock in two tranches to...
Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
August 16, 2016 16:33 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of William Shanahan, M.D., J.D. as Chief Medical Officer. In...
Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™
August 16, 2016 08:46 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned...
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
August 09, 2016 08:35 ET
|
Anthera Pharmaceuticals, Inc.
Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of Sollpura™Successful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration...
Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod
August 03, 2016 16:05 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the last patient in the Phase 3 CHABLIS-SC1 clinical study, evaluating...
Anthera Provides Clinical Program Updates for Blisibimod and Sollpura®
June 28, 2016 17:00 ET
|
Anthera Pharmaceuticals, Inc.
Positive trends from BRIGHT-SC proof-of-concept study – study to continueSOLUTION study with Sollpura completed patient screening ahead of schedule – data in 2016First patients screened in Phase 3...